NICE reverses Gazyvaro rejection in latest draft guidance
This article was originally published in Scrip
Executive Summary
NICE has issued new draft guidance recommending Roche's Rituxan (rituximab) follow-on Gazyvaro (obinutuzumab) for some people with chronic lymphocytic leukemia (CLL), just two months after issuing preliminary guidance rejecting it (scripintelligence.com, 7 October 2014).